Cvs Health Corp (CVS): Larry J Merlo , President and CEO of Cvs Health Corp sold 38,247 shares on May 5, 2016. The Insider selling transaction was reported by the company on May 6, 2016 to the Securities and Exchange Commission. The shares were sold at $105.00 per share for a total value of $4,015,935.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 6, 2016, Troyen A Brennan (EVP and Chief Medical Officer) sold 7,517 shares at $105.00 per share price.On Apr 5, 2016, Andrew Sussman (EVP & Pres, CVS MinuteClinic) sold 2,844 shares at $105.00 per share price.Also, On Apr 5, 2016, Stephen J Gold (EVP & CIO) sold 21,922 shares at $105.00 per share price.On Mar 11, 2016, Larry J Merlo (President and CEO) sold 38,247 shares at $100.00 per share price.
Shares of CVS Health Corp (CVS) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -0.02% at $103.9 with 46,17,044 shares getting traded. Post opening the session at $102.93, the shares hit an intraday low of $102.93 and an intraday high of $104.42 and the price vacillated in this range throughout the day. The company has a market cap of $114,133 M and the number of outstanding shares has been calculated to be 1,09,84,90,840 shares. The 52-week high of CVS Health Corp is $113.65 and the 52-week low is $81.37.
Company has been under the radar of several Street Analysts.CVS Health Corp is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 117 from a previous price target of $104 .The Rating was issued on May 4, 2016.CVS Health Corp is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 115 from a previous price target of $110 .The Rating was issued on May 4, 2016.CVS Health Corp is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 115 from a previous price target of $110 .The Rating was issued on Mar 10, 2016.CVS Health Corp is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 104 from a previous price target of $113 . The Rating was issued on Feb 10, 2016.
CVS Health Corporation together with its subsidiaries is a pharmacy company. The Company operates through three business segments: Pharmacy Services Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services Novologix and Navarro Health Services names. The Retail Pharmacy segment sells prescription drugs and an assortment of general merchandise including over-the-counter drugs beauty products and cosmetics personal care products convenience foods photo finishing seasonal merchandise and greeting cards through the Company’s retail stores online retail pharmacy Websites and retail healthcare clinics. The Corporate segment provides management and administrative services to support the overall operations of the Company. The Company through its wholly owned subsidiary Omnicare Inc. provides pharmacy services to long term care facilities.